Chengda Biotech announced that the influenza virus lysis vaccine developed by the Benxi subsidiary, a wholly-owned subsidiary of the company, has been approved for clinical trials by the State Drug Administration, has completed preparations, and officially entered phase I clinical trials. The influenza vaccine can prevent influenza. The company's vaccine has a higher antigen content and a stronger immune effect, which is expected to fill the gap in the domestic market. However, the vaccine development cycle is long, there are many steps, and the process, results, and marketing progress are uncertain, and there is little impact on the company's operations in the short term.

Chengda Biotech announced that the influenza virus lysis vaccine developed by the Benxi subsidiary, a wholly-owned subsidiary of the company, has been approved for clinical trials by the State Drug Administration, has completed preparations, and officially entered phase I clinical trials. The influenza vaccine can prevent influenza. The company's vaccine has a higher antigen content and a stronger immune effect, which is expected to fill the gap in the domestic market. However, the vaccine development cycle is long, there are many steps, and the process, results, and marketing progress are uncertain, and there is little impact on the company's operations in the short term.